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A retrospective determination of the time of metastasis formation is essential for a better understanding of the evolution of
oligometastatic cancer. This study was based on the hypothesis that genomic alterations induced by cancer therapies could be
used to determine the temporal order of the treatment and the formation of metastases. We analysed the whole genome
sequence of a primary tumour sample and three metastatic sites derived from autopsy samples from a young never-smoker
lung adenocarcinoma patient with an activating EGFR mutation. Mutation detection methods were reﬁned to accurately detect
and distinguish clonal and subclonal mutations. In comparison to a panel of samples from untreated smoker or never-smoker
patients, we showed that the mutagenic effect of cisplatin treatment could be speciﬁcally detected from the base substitution
mutations. Metastases that arose before or after chemotherapeutic treatment could be distinguished based on the allele
frequency of cisplatin-induced dinucleotide mutations. In addition, genomic rearrangements and late ampliﬁcation of the EGFR
gene likely induced by afatinib treatment following the acquisition of a T790M geﬁtinib resistance mutation provided further
evidence to tie the time of metastasis formation to treatment history. The established analysis pipeline for the detection of
treatment-derived mutations allows the drawing of tumour evolutionary paths based on genomic data, showing that
metastases may be seeded well before they become detectable by clinical imaging.
Introduction
Metastatic progression makes an important contribution to the
mortality of multiple cancer types, but clinical imaging provides
limited information on when metastases ﬁrst arise, and whether
they are already present at the time of the ﬁrst treatment.
Genomic analyses can retrospectively help understanding the
evolution of a tumour and distinguishing between early or late
metastasis formation.1,2 Our aim was to use the example of
lung adenocarcinoma to tie metastasis formation to timed
events in the patient’s treatment history. An improved knowl-
edge of the typical times of metastatic seeding could help with
weighing surgical and medical treatment options.
Multiregion sequencing has been used for mapping evolu-
tion within the primary tumour in lung adenocarcinoma,3,4
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and post-mortem sequencing of metastases can elucidate what
further genomic changes take place during metastasis forma-
tion.5,6 However, multiregion whole genome sequencing
(WGS) studies, which provide the broadest and most reliable
view on somatic mutagenesis and gene copy number
changes,7,8 have not been performed in lung cancer. Even with
available WGS data, it is difﬁcult to obtain timing information
for the evolutionary steps from contemporaneous samples. In
the current study we reasoned that if treatments leave recogni-
sable marks on the genome, the treatment-related mutations
could provide extra information for the timing of evolutionary
branchpoints and metastasis formation.
We have recently demonstrated the mutagenicity of the
cytotoxic agents cisplatin and cyclophosphamide in cell line-
based studies,9 and an experimentally derived cisplatin muta-
tion spectrum was subsequently found in cisplatin-treated
esophageal and liver tumours.10 If certain somatic mutations
in tumour samples can be assigned to a treatment agent that
the patient received, then the branching time of two samples
can be determined relative to the time of the treatment based
on whether the treatment-derived mutations in two samples
are unique or shared. Accurate mutation detection is critical
for such analyses, confounded by varying tumour content and
the varying allele frequency (AF) of subclonal mutations,
necessitating a careful bioinformatics approach.
Treatments may also select for known, identiﬁable resistance-
causing mutations,11 whose appearance can help understanding
evolutionary paths.
In order to study the evolution of lung adenocarcinoma, we
performed whole genome sequencing on the primary tumour
and multiple metastases of a young non-smoker patient with
EGFR mutant cancer. In addition to kinase activating muta-
tions, EGFR may also be subjected to genomic ampliﬁcation.
Treatment with tyrosine kinase inhibitors almost invariably
leads to resistance, in about half the cases through the acquisi-
tion of an EGFR T790M mutation.12,13 We were able to detect
ongoing EGFR ampliﬁcation following the acquisition of geﬁti-
nib resistance through T790M mutation, and importantly also
showed that mutations caused by cisplatin treatment can be
used to time the formation of metastases. The demonstrated
analysis pipeline allows the drawing of tumour evolutionary
paths, which in this case distinguish metastases formed before
and after the cisplatin treatment, and also show the progress of
cells through the same lymph node to distinct distant metastases.
Materials and Methods
DNA isolation
Written informed consent was obtained from the patient to per-
form genomic analyses of the tumour and peripheral blood sam-
ples. Permissions to use the archived tissue have been obtained
from the Regional Ethical Committee (No: 510/2013, 86/2015).
Peripheral blood taken during routine diagnostic tests was
collected and frozen. Primary tumour and metastasis samples
were collected and frozen during autopsy. The formalin-ﬁxed
parafﬁn embedded bronchoscopy biopsy sample of the primary
tumour was also used in this study. Genomic DNAs were
extracted with the High Pure PCR Template Preparation Kit
(Roche) according to the manufacturer’s recommendations.
DNA sequencing
One hundred and ﬁfty basepairs paired end whole genome
DNA sequencing to a mean coverage of 60× (peripheral
blood) or 61×-86× (tumour samples) was performed on Illu-
mina HiSeq X Ten instruments at Edinburgh Genomics
(Edinburgh, UK). For detailed coverage information, see Sup-
porting Information Methods.
Somatic mutation calling
Alignment of the sequencing reads to the reference genome
GRCh38/hg38 was performed with the Burrows-Wheeler align-
ment algorithm,14 followed by post-processing with the IndelRea-
ligner tool of the Genome analysis Toolkit (GATK, version 3.4).15
Somatic mutations, insertions and deletions were obtained
using the GATK MuTect2 mutation caller.16 The merged list
of mutation positions identiﬁed by MuTect2 from all samples
was used to detect subclonal mutations. This was done by
extracting the AFs directly from the binary alignment (BAM)
ﬁles. The supplemented data set was subjected to carefully opti-
mised post-ﬁltering (see Supporting Information Methods). In
the ﬁnal ﬁlter, one mutation-containing read was allowed in the
control blood sample to allow for index switching noise.17 For
the tumour samples, 0 or at least 3 mutation containing reads
were allowed, considering the positions with 1 or 2 mutated
reads as potential noise.
Germline and somatic DNA analysis
GATK HaplotypeCaller was used to detect all germline varia-
tions in the genome. The determined polymorphisms were ana-
lysed and annotated with InterVar.18 Mutations classiﬁed as
‘likely pathogenic’ or ‘pathogenic’ were considered. The somatic
What’s new?
Cancer treatment induces mutations either through direct DNA damage or through the evolutionary selection of resistance
mutations. The authors exploited this effect to study temporal tumor phylogeny and the formation of metastases. Using whole-
genome sequences isolated from a patient with lung adenocarcinoma, they identify metastases that arose before or after onset
of treatment with platinum and tyrosine kinase inhibitors, underscoring that metastases develop and need to be treated much
earlier than they become clinically apparent.
2 The genomic imprint of cancer therapies
Int. J. Cancer: 00, 00–00 (2019) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
C
an
ce
r
G
en
et
ic
s
an
d
E
pi
ge
n
et
ic
s
mutations determined by MuTect2 and the post-processing
were also annotated with InterVar.
Structural variations
Structural variants were determined by the CREST algo-
rithm.19 Post-ﬁltering was performed with the condition of
minimum 3 reads at both the left and right clipped chromo-
some. Chromosome translocations were visualised with the
circlize R package.20
Estimation of tumour content and EGFR allele numbers
Tumour content of the samples was estimated based on the
heterozygous polymorphisms (SNPs) in the TP53 gene, located
in a region with loss of heterozygosity and normal coverage.
AFs at these SNPs were used to determine tumour content
with high precision as an average of the estimated tumour con-
tent in each of these positions.
The genomic region around the EGFR gene presented an
increased coverage in the tumour samples because of ampliﬁ-
cation. To determine the number of alleles containing the
exon 19 deletion (e19del) mutation we used the AF at this
site, corrected with the deletion-related drop in coverage and
the tumour content determined from TP53 polymorphisms.
The possibility of the ampliﬁcation of WT allele in tumour
cells was rejected based on estimations from the nearby poly-
morphisms. Based on the tumour content and EGFR e19del
alleles the number of alleles simultaneously containing the
T790M mutation could be estimated in a similar manner (see
Supporting Information Methods for more details).
Decomposition of mutational spectra
The sequence context of the preceding and following base was
determined for each mutation. The resulting triplet SNV spec-
tra, were analysed for contributions of known mutational sig-
natures in the COSMIC cancer mutation database.21 The
deconstructSigs R package22 was applied using a restricted set
of COSMIC signatures that included ageing and tissue-speciﬁc
cancer signatures1,2,4–6,12,13,15–17,23 supplemented with the sig-
nature drawn from cisplatin-treated human cell lines,10 and
with a minimum signature contribution of 6%.
Analysis of TCGA data
WGS BAM ﬁles of treatment naïve lung cancer cases were
downloaded from The Cancer Genome Atlas (TCGA).
Somatic mutations were called by MuTect2 and were used to
construct the 96 category-based triplet SNV spectra. These
were deconstructed using COSMIC and cisplatin signatures as
described above.
Model drawing
The qualitative model of tumour evolution was built using
ﬁgures constructed with the ﬁshplot R package.23
Data access
Binary alignment map (BAM) ﬁles of the primary tumour, the
bone, liver, lymph node metastases, and the peripheral blood
sample, as well as the mutational data including SNVs, DNVs,
short insertions and deletions and chromosome translocations
are accessible at the European Genome-phenome Archive
under study ID EGAS00001003416.
Results
The collection of post-chemotherapy metastatic tumour
samples
WGS data deposited in databases usually originates from the
time before chemotherapy, hampering the analysis of the
genetic effects of the treatments. For this study numerous
samples were collected from a complex metastatic lung adeno-
carcinoma case, in which cisplatin chemotherapy was applied
prior to the clinically detectable emergence of the sampled
metastases. The course of the disease and the treatment his-
tory are shown on Figure 1.
Geﬁtinib therapy was started on the exon 19 deletion
(e19del) positive EGFR mutant tumour, and subsequent chest
CTs showed partial response (Supporting Information Fig. S1).
Sixteen months later an EGFR T790M resistance mutation was
detected in a bronchoscopy biopsy sample of the primary
tumour. Further treatments included one cycle of pemetrexed-
cisplatin chemotherapy, followed by pemetrexed monotherapy,
and a switch to the second generation irreversible EGFR inhibi-
tor afatinib (Fig. 1 and Supporting Information Fig. S1). Sam-
ples were taken from the primary tumour and the vertebral,
liver and paratracheal lymph node metastases at autopsy. None
of these metastases were observable during the preceding clini-
cal investigations. A detailed description of the clinical observa-
tions and sample collection can be found in the Supporting
Information Methods.
Accurate detection of somatic mutations in metastatic
cancer
An initial attempt at detecting somatic single nucleotide varia-
tions (SNVs) and small insertions and deletions (indels) was
made using MuTect216 on each sample versus a sequenced
peripheral blood (PB) DNA sample. Using this pipeline, we
detected a total of 17,415 SNVs and 4,412 indels (Supporting
Information Fig. S2). We found fewer mutations in the sam-
ples with lower tumour content (lung and lymph node), sug-
gesting that a fraction of low AF mutations were missed in
these samples. In addition, we found a considerable number
of mutations common to any combination of tumour samples,
which is incompatible with drawing a phylogenetic tree. Based
on the common origin of the tumour sites, we were able to
extract further low AF mutations from the raw data. After
subsequent ﬁltering, we increased the number of detected
mutations common to all samples and reduced the number of
paradoxical mutations common to various subsets of the sam-
ples (Supporting Information Figs. S2 and S3, more details in
Németh et al. 3
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the Supporting Information Methods). Similar post-ﬁltering
steps were used for indels. The resulting ﬁnal data set con-
tained a total of 9,832 SNVs, 330 insertions and 485 deletions
(Figs. 2a–2d). The distribution of the SNV AFs suggested
higher tumour content in the bone and liver metastasis sam-
ples, but double AF peaks in the same samples indicate that
subclonal mutations were also found (Fig. 2e).
Only two driver mutations in metastatic lung
adenocarcinoma
To understand the genetic drivers of the investigated primary
tumour and its metastases, we ﬁrst looked for somatic muta-
tions that are classiﬁed as pathogenic or likely pathogenic by
the InterVar tool.18 We found in all samples the EGFR kinase-
activating e19del mutation, and the EGFR T790M mutation
responsible for geﬁtinib resistance (Supporting Information
Table S1). In addition, a homozygous TP53 R280T mutation was
present in all samples, resulting from a loss-of-heterozygosity
event on chromosome 17. The same TP53 mutation has been
repeatedly observed in lung adenocarcinoma (LUAD) as well as
other cancer types.24 No further somatic drivers common to all
samples were found, suggesting that EGFR activation and TP53
inactivation were sufﬁcient to trigger lung adenocarcinoma.
Potentially pathogenic somatic mutations were found in
one allele of the XRN1, EVC2 and FGA genes in subsets of the
samples (Supporting Information Table S1). XRN1 has been
suggested as a candidate tumour suppressor gene in
osteosarcoma,25 but none of these three genes have been con-
ﬁrmed as oncogenic drivers in lung cancer. Therefore, it
appears that the formation of metastases was not induced by
the acquisition of extra driver mutations.
Six genes contained potentially pathogenic heterozygous
germline mutations (Supporting Information Table S1). The
RET T791Y mutation was most interesting as it can trigger the
ligand-independent activation of the RET receptor, thereby
contributing to the activation of the JAK/STAT3 pathway.26
Although RET activating mutations are widely found in thy-
roid cancers, only rearrangements of the RET gene are com-
mon in NSCLC.27 Indeed, while the RET Y791F mutation was
initially considered a low risk mutation, it was later reclassiﬁed
as a likely non-pathogenic polymorphism.28,29
Somatic mutagenesis across multiple metastases
Patterns of somatic mutations in cancer genomes provide
important information concerning tumour aetiology.30 When
viewed as triplet mutation patterns in the context of the
neighbouring bases, the SNV patterns in the four tumour
samples were very similar (Fig. 2f ). All categories of base sub-
stitutions were present, with a slight dominance of C > T and
C > A mutations. When compared to common cancer muta-
tional signatures21,31 the SNV patterns of the analysed lung
adenocarcinoma samples bore closest resemblance to the simi-
larly broad-spectrum signatures 5, 8 and 3, and little resem-
blance to the smoking-related signature 4, in agreement with
the non-smoking history of the patient (Fig. 2g). The spec-
trum of common mutations, indicative of mutagenesis early
in the life of the tumour, was also similar to the SNV spectra
of the individual metastatic samples (Fig. 2g and Supporting
Information Fig. S4). The lack of a marked difference between
the mutagenic processes in the early tumour and the different
metastases is in agreement with the lack of novel driver muta-
tions in metastases, and also suggests that the changed tissue
environment following metastasis formation had no inﬂuence
on mutagenesis in tumour cells.
Detection of cisplatin treatment-derived mutations
The main aim of this study was to detect and utilise treatment-
induced mutations for the purpose of understanding the history
1 5 17 25 33
autopsy
brain metastasis 1 
bone metastasis 1 
EGFR e19del EGFR T790M
afatinib
primary lung adenocarcinoma *
*
*
*
brain metastasis 2 
gefitinib
cisplatin
treatment
time (months)
EGFR mutation
bone metastasis 2
liver metastasis
LN metastasis
Figure 1. Disease history of the young never-smoker patient. The main diagnostic events and relevant treatments are shown over a timeline
in months. Collected samples are indicated with asterisks. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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of metastatic tumours. Our expectation was that treatment-
induced mutations would likely be subclonal if the treatment
hit an existing tumour site or metastasis, but clonal if a metasta-
sis was formed from a single seeding cell following the
treatment. We could indeed detect mutations with different
AFs (Fig. 3a).
SNVs common to all tumour sites had pronouncedly
higher AF in the lung, bone and lymph node sample than
(a) (b)
(c)
(f) (g)
(d)
(e)
Figure 2. Characterisation of mutations in whole genome sequences. (a) Number of SNVs in the lung, bone, liver and the lymph node
(LN) samples. The PB column accounts for those mutations that are present in the peripheral blood sample with one sequence read,
originating mainly from noise. (b) Number of insertions and deletions. (c, d) Venn diagrams showing the distribution of SNVs and indels
amongst the samples, respectively. (e) Distribution of allele frequencies of the detected SNVs. (f ) Triplet SNV spectra of the tumour samples.
Each mutation class, as indicated at the top of the panel, is separated into 16 categories based on the identity of the preceding and
following nucleotide as shown below. The order of the following nucleotides, not shown due to lack of space, is alphabetical. (g) Similarity of
the determined triplet spectra (purple) to COSMIC cancer signatures (numbered) as shown on a t-distributed stochastic neighbour embedding
(t-SNE) plot. The spectrum of mutations that are unique (u) to individual samples, common to all samples, and the cell line-derived cisplatin
spectrum are also shown. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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unique SNVs, suggesting that we could detect subclonal muta-
tions in the unique SNV pool (Supporting Information
Fig. S5). Dinucleotide mutations (DNVs) had a similar AF
distribution to unique SNVs in all samples, and we could con-
ﬁrm that the majority of DNVs were unique to individual
tumour samples (Fig. 3b and Supporting Information Fig. S6).
DNVs associate with certain SNV signatures,32 and are other-
wise rare in cancer genomes. However, we showed earlier that
cisplatin induces speciﬁc types of dinucleotide mutations at
sites of intrastrand crosslinks9 and the cisplatin treatment of
human cell lines led to a closely related pattern of DNV muta-
tions to what we found in chicken DT40 cells.10 Remarkably,
we found very similar types of DNVs in the sequenced
samples to those induced by cisplatin in cell lines (Figs. 3c
and 3d). The most common types of DNVs were CC > AA
and CT > AA, consistent with mutations forming at G G^ and
A G^ cisplatin intrastrand adducts.
To further explore whether the single cycle of cisplatin
treatment administered to the patient was mutagenic, we
deﬁned a cisplatin-induced triplet SNV signature based on the
mutation spectrum of cisplatin-treated human cell lines10 and
looked for its contribution to the detected SNV pools. A
decomposition into all triplet signatures implicated in cancers
of the lung and the sampled metastatic sites in COSMIC,21
plus the cisplatin signature, revealed a contribution of the cis-
platin SNV signature to unique mutations in the lung primary
tumour sample as well as in the bone and lymph node metas-
tases (Fig. 4a), but not to mutations detected in TCGA-
derived whole genome LUAD or LUSC sequences of either
non-smoker or smoker patients who did not receive prior cis-
platin chemotherapy (Fig. 4b), suggesting that we speciﬁcally
detected cisplatin-induced SNVs in the samples from the trea-
ted patient.
The DNV spectra of the TCGA samples were also mark-
edly different from those of our sequenced samples, with the
samples from smokers dominated by CC > AA mutations
(Figs. 4c and 4d and Supporting Information Fig. S7). Also,
the DNV spectrum of our four sequenced samples was signiﬁ-
cantly more similar to the cell line-derived cisplatin spectrum
than that from the TCGA samples from either lifelong non-
smokers or current smokers (Fig. 4e; p = 1.963 × 10−4 and
p = 2.416 × 10−7, respectively, t-test). Our results conclusively
prove that even a single cisplatin treatment induces detectable
SNV and DNV mutagenesis in lung cancer genomes.
Ongoing structural rearrangements affect the EGFR gene
A further genomic consequence of treatment was the emer-
gence of the EGFR T790M mutation responsible for geﬁtinib
resistance. Irreversible inhibition of T790M-EGFR can induce
the ampliﬁcation of the mutation containing allele,33 and afa-
tinib resistance has been shown to be accompanied by ele-
vated EGFR expression in cell lines.34 In order to investigate
whether the afatinib treatment induced variations in the EGFR
gene, we performed a copy number analysis. The sequence
coverage at the EGFR locus and the whole chromosome
7 revealed that the EGFR gene also underwent ampliﬁcation
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Figure 3. Characterisation of DNVs. (a) Allele frequency distribution of DNVs as compared to the SNVs, classiﬁed based on the Venn diagram
(unique if found only in one sample and common if found in all four tumour samples). (b) Venn diagram of DNVs. (c, d) Sequence categories
of DNVs. The categories most predominant in the cisplatin treated human cell lines10 (d) are shown in black boxes. [Color ﬁgure can be
viewed at wileyonlinelibrary.com]
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(Figs. 5a and Supporting Information Fig. S8), a phenomenon
that is commonly observed in EGFR-mutated LUAD.
To estimate the timing of the ampliﬁcation events, we
determined the copy number of each EGFR allele using AF
information and tumour content data precisely calculated
from germline SNP AFs at the TP53 locus that underwent loss
of heterozygosity (Figs. 3a and Supporting Information
Fig. S9) and assuming that the T790M mutation occurred on
the e19del EGFR bearing allele.35 Each sample was different:
in addition to one normal allele, the primary tumour con-
tained one e19del allele and ten additional e19del+T790M
alleles, while the metastases contained two e19del alleles and
one or two e19del+T790M alleles (Fig. 5b). In the lymph node
sample, the calculation showed very close to 1.5 copies of the
e19del+T790M allele; we suspect this is due to a mixture of
two cell populations in this sample (see below). The last com-
mon ancestor of the primary tumour and the three sampled
metastases had at most three copies of EGFR: a wild type, an
e19del and an e19del+T790M allele, though our results cannot
exclude the possibility that the T790M mutation arose several
times independently. These data show that either the deletion-
activated or the TKI-resistant EGFR allele may undergo
ampliﬁcation, and that such ampliﬁcation events continue
after metastasis formation.
Searching for a mechanism for EGFR ampliﬁcation, we
looked for genome-wide patterns of structural variations (SVs).
Uneven sequence coverage across the whole genome suggested
the presence of many rearrangements (Supporting Information
Fig. S10), and we detected numerous translocation breakpoints
using the CREST algorithm. Interestingly, most translocations
were unique to the lung and liver samples, though a set of the
liver translocations were also present in the lymph node sample
at low AF (Figs. 5c and 5e). There was an especially high num-
ber of low AF subclonal breakpoints in the lung sample
(Supporting Information Fig. S11). We selected two breakpoints
downstream of the EGFR gene (Fig. 5a), and conﬁrmed by
PCR across the breakpoints that these two translocations
between chromosomes 2 and 7 were not present in the bron-
choscopy biopsy sample taken at the time of the emergence of
the T790M mutation (Figs. 1a and 5d). All these observations
(a) (b)
(c) (d) (e)
Figure 4. The mutagenic effect of cisplatin treatment. (a) Decomposition of SNV spectra to a selection of COSMIC signatures supplemented
with the cisplatin spectrum as deﬁned in Boot et al.10 (b) A similar SNV spectrum decomposition on TCGA-derived WGS LUAD and LUSC
samples of never-smoker and smoker patients, not treated with cisplatin. (c, d) DNV sequence categories in case of never-smoker and
smoker patients, with black boxes indicating the cisplatin type mutations. (e) RMSD of the DNV spectra from the cell line-derived DNV-
spectrum. The four samples from the cisplatin-treated patient are compared to smoker and non-smoker patient data from TCGA. [Color ﬁgure
can be viewed at wileyonlinelibrary.com]
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point to ongoing large-scale genome instability late in the his-
tory of the tumour, which may provide the selectable events
leading to EGFR ampliﬁcation.
A phylogenetic model for tumour growth and spread
The distribution of somatic mutations amongst the samples
allows the construction of simple tumour phylogeny.36 Our
aim was to use the distribution and AF of treatment-induced
mutations to augment a phylogenetic tree with timing infor-
mation. The Venn diagram of high AF somatic mutations
with the strictest ﬁlter suggests a simple phylogeny whereby
the bone metastasis is an almost direct descendant of the
lymph node metastasis, while the liver metastasis evolved sep-
arately (Supporting Information Fig. S2E). However, the
inclusion of low AF mutations in the ﬁnal ﬁltering revealed
two exclusive groups of SNVs in the lymph node that are
shared with either the bone or the liver metastasis. Both of
these groups are subclonal, with a mean AF of 0.11 and 0.06,
respectively, while the clonal common mutations have a mean
AF of 0.14 (Supporting Information Fig. S5), in agreement
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Figure 5. Structural variations identiﬁed with the CREST algorithm. (a) Ampliﬁcation of the EGFR gene demonstrated by the increased
coverage of the aligned sequence. B1 and B2 indicate two mapped breakpoints. (b) Copy numbers of the WT, exon19del and T790M
containing EGFR alleles, estimated based on the calculated tumour content and the coverage at the EGFR positions, as well as the allele
frequencies of heterozygous polymorphisms, the coverage of the T790 position and allele frequency of the T790M mutation. (c) Venn
diagram of identiﬁed chromosomal translocations. (d) PCR from the autopsy samples and the bronchus biopsy sample conﬁrms the late
formation of the B1 and B2 breakpoints. (e) Chromosomal translocations shown on genomic chord diagrams. The translocations are coloured
based on their allele frequencies. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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with the calculated tumour content of the lymph node sample
(26%). This suggests that the lymph node sample contained
two distinct groups of tumour cells related to either the bone
or the liver metastasis, implying that the seeding route for
both these distant metastases led through the same parathra-
cheal lymph node (Fig. 6). Thus the improved ﬁltering of low
AF mutations allows the reﬁnement of tumour phylogeny.
The AF distribution of DNVs, which are mostly cisplatin-
induced, closely matches that of common SNVs in the liver
metastasis, thus they must be clonal. We can conclude that
the ancestor of the liver metastasis sample was a single cell at
the time of the cisplatin treatment, therefore this metastasis
likely arose after the treatment. The contribution of the cis-
platin SNV signature to mutations shared by the liver and
lymph node but not to unique liver mutations also conﬁrms
the clonality of these mutations in the liver sample, and places
the origin of the liver metastasis in the lymph node. In con-
trast, cisplatin-induced DNVs are subclonal in the bone and
lymph node metastases, which must therefore have existed
before the treatment despite being undetectable by clinical
imaging. With the caveat that a sampled site cannot fully
reﬂect the clonality of the full metastatic site, these data allow
the drawing of a timed phylogenetic tree (Fig. 6); also showing
early and late EGFR ampliﬁcation events gleaned from the
study of rearrangements.
Discussion
In this study, we were able to directly demonstrate and mea-
sure the mutagenic effect of cisplatin treatment on lung ade-
nocarcinoma, and use this information together with a
detailed analysis of genome sequences of primary and meta-
static tumour sites to build a timed model of tumour
development.
The mutagenicity of cytotoxic therapy is a concern due to
the potential of induced mutations to accelerate the evolution
of resistance in cancer cells, and to trigger carcinogenic
changes in normal tissue. In a DT40 cell culture model we
previously estimated the mutagenicity of cisplatin treatment at
IC50 concentration as 200 base substitutions per gigabase per
treatment cycle,9 and not entirely comparable weekly treat-
ments of MCF10A and HepG2 cells caused 150–450 base sub-
stitutions per gigabase per treatment.10 To ﬁnd the
mutagenicity of cisplatin per tumour cell, we must consider
only clonal mutations in the sequenced samples. Eight percent
of the 476 SNVs common to the liver and lymph node sam-
ples belong to the cisplatin signature, and these mutations are
Primary lung
sample
Brain metastasis
gefitinib
EGFR
T790M 
p53 R280T
EGFR e19del
cisplatin afatinib
EGFR
amplification 1 
EGFR amplification 2
genome-wide SV 
genome-wide
SNV, DNV
WGS
LN metastasis
sample
Bone metastasis
sample
Liver metastasis
sample
cisplatin mutations
EGFR amplification 2
EGFR amplification 1
founder mutations
EGFR T790M
Figure 6. A qualitative model showing the relationship between the primary tumour and metastases. Cisplatin-induced mutant subclones are
depicted. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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clonal in the liver metastasis, suggesting that at least 13 SNVs
per gigabase were induced by cisplatin in its single ancestral
cell. An alternative estimate can be obtained from the number
of DNVs, which were present at about 7.5% of the number of
SNVs in both of the above studies. In the liver sample there
were 17 clonal DNVs attributable to the cisplatin effect, lead-
ing to an estimate of 75 SNVs per gigabase. These estimates
are lower than the cell line-based observations, suggesting
more limited access of the drug to tumour cells. LUAD
genomes from smokers or never-smokers contain a mean of
12,100 and 2,600 mutations per gigabase respectively,37 but
these mutations accumulated over decades, therefore repeated
cycles of cisplatin treatment probably signiﬁcantly increase the
mutation rate and contribute to the evolution of resistance.
The dominance of cisplatin-induced mutations amongst all
DNVs in cell lines and tumours from a never-smoker suggests
that a DNV spectrum can be used for more sensitive detection
of cisplatin-induced mutagenesis than an SNV spectrum.
Smoking also induces a high number of mainly CC > AA
DNVs, but we were able to distinguish the smoking DNV
spectrum from the cisplatin-induced DNVs. Finding clonal
cisplatin-induced DNVs in a metastatic tumour sample is
therefore a simple method for ascertaining that the given
metastasis arose after cisplatin treatment of the patient.
In the investigated LUAD case the liver metastasis
appeared late, and the data also proves that it was seeded from
a single cell or cell clone. In contrast, the subclonality of cis-
platin mutations in the bone and lymph node metastases sug-
gests that the metastatic process that initiated their formation
had begun prior to the treatment, even though the sampled
metastases were not observed at that time. Subclonality of
somatic mutations in metastases can also suggest polyclonal
seeding.38,39 We observed evidence for this in the lymph node
metastasis, similar to recently reported data from colon can-
cer.40 The clonal state of the same mutations at two other sites
suggests that this subclonality was due to the anatomical loca-
tion and seeding routes of the respective metastases rather
than a cooperative interaction of the two cell populations.41
The shared seeding routes through the same proximal lymph
node metastasis to distant metastases may be a trait of
oligometastatic LUAD.
EGFR ampliﬁcation is associated with more aggressive
tumours, and often occurs at a late stage of the disease.42 The
presence of extreme EGFR ampliﬁcation only in the primary
site suggests that it was indeed a late event in this case, also
supported by the subclonality of the ampliﬁcation breakpoints
upstream of the gene. The therapy was switched from geﬁtinib
to afatinib following the seeding of metastases, raising the pos-
sibility that the ampliﬁcation was a response to increase the
afatinib resistance of the tumour that already contained the
EGFR T790M mutation. The ampliﬁcation of the EGFR gene
occurred via chromosomal translocations, and other late stage
structural variations were also identiﬁed in the primary
tumour and the liver metastasis. A number of the liver-
speciﬁc clonal chromosome translocations were found as sub-
clonal events in the lymph node, supporting the conclusion
that the liver metastasis was seeded at the last stages of the
disease, after the switch to afatinib.
The detection of clonal tumour evolution from high-
coverage WGS samples has been described,43 and various
strategies have been reported for analysing clonal evolution
from WGS data.44,45 The analysis of clonal composition of
tumours has showed that subclones can contribute to meta-
static seeding and establish resistance to treatments.46,47 Evo-
lutionary studies of a glioblastoma case have demonstrated
the importance of understanding of the subclonal events for
personalised therapy.48 Treatments can also induce subclonal
events, but few WGS studies have addressed this question.
The effect of aromatase inhibitors on clonal architecture was
shown by WGS analysis of matched tumour-normal pairs
before and after neoadjuvant therapy in oestrogen-receptor-
positive breast cancers,49 and resistance and clonal advantage
after therapy was identiﬁed in circulating tumour DNA in
chronic lymphocytic leukaemia.50 Here we showed for the ﬁrst
time that the analysis of subclonal events in matched meta-
static tumour samples can also be used for a retrospective
analysis of the timing metastatic events, even using standard-
coverage WGS data, contributing to our understanding of the
evolution of oligometastatic disease, as well as of the genomic
imprint of chemotherapeutic treatments.
In conclusion, we have demonstrated the use of genomics
to map the progress of metastatic cancer, making use in par-
ticular of information derived from the mutagenic effect of
cisplatin therapy. As in related studies, the conclusions on
clonality are limited by the size of the tissue sample in relation
to the tumour site. Nevertheless, we used the obtained infor-
mation to show that early and late metastases may seed
through the same proximal lymph node, and that independent
late EGFR ampliﬁcation events at different sites contribute to
the ongoing evolution of the lung adenocarcinoma. Tumour
type speciﬁc studies on the timing of metastasis formation rel-
ative to established treatment practices will be valuable for
shaping future therapy regimens.
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